U.S. FTC raises concerns over dominant Pharmacy Benefit Managers (PBMs) influencing prescription drug prices at the expense of independents and consumers.
The U.S. Federal Trade Commission (FTC) has revealed concerns over the influence of a few dominant Pharmacy Benefit Managers (PBMs) on prescription drug prices, suggesting they have profited at the expense of independent pharmacies and consumers. An interim report highlights how increasing vertical integration and concentration has enabled the six largest PBMs to manage nearly 95% of all prescriptions filled in the U.S. The FTC's report reveals that these PBMs have been able to significantly influence what drugs are available and at what price, giving them outsized control over the healthcare industry.
July 09, 2024
29 Articles